Fibroblast Activation Protein Inhibitors Global Market Report 2025

The fibroblast activation protein inhibitors market size has grown rapidly in recent years. It will grow from $2.74 billion in 2024 to $3.02 billion in 2025 at a compound annual growth rate (CAGR) of 10%. Growth during the historic period can be attributed to the growing emphasis on personalized medicine, increased investment in oncology drug discovery, the advancement of biomarker-based drug development, expanding collaboration among biotechnology companies, and heightened interest in targeting the tumor stroma as a therapeutic approach.

The fibroblast activation protein inhibitors market size is expected to see strong growth in the next few years. It will grow to $4.37 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. Growth in the forecast period can be attributed to the expanding pipeline of fibroblast activation protein (FAP) inhibitors, broader applications in non-oncology conditions, increasing use of combination therapies, rising government funding for cancer research, and growing interest from pharmaceutical companies. Key trends expected during this period include advancements in targeted drug delivery systems, the development of next-generation FAP inhibitors, innovation in companion diagnostic technologies, progress in immunotherapy combination strategies, and the formulation of oral delivery options to enhance patient compliance.

The rising incidence of cancer is expected to drive the growth of the fibroblast activation protein (FAP) inhibitors market in the coming years. Cancer is characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body, originating in various tissues and classified based on their cell or tissue of origin. The growing number of cancer cases is attributed to factors such as aging populations, lifestyle changes, environmental exposures, and improvements in diagnostic methods. FAP inhibitors are used in oncology to target tumor-supporting fibroblasts, thereby enhancing both diagnostic imaging and the delivery of cancer therapies. For example, in August 2024, Macmillan Cancer Support, a UK-based charitable organization, reported that over 3 million people in the UK were living with cancer in 2024, with projections indicating this number will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing incidence of cancer is fueling the expansion of the FAP inhibitors market.

Leading companies in the fibroblast activation protein (FAP) inhibitors market are increasingly incorporating SAR chelator technology with FAP targeting to enhance the precision of radiopharmaceutical delivery, improve diagnostic imaging accuracy, and boost therapeutic effectiveness in cancer treatment. SAR chelator technology involves the use of specialized molecules that securely bind radioactive metals, enabling researchers to assess how structural changes influence drug performance. This technology is primarily applied to guide radioactive agents directly to cancer cells for imaging or therapeutic purposes. For example, in December 2024, Clarity Pharmaceuticals, an Australia-based radiopharmaceutical company, introduced its innovative FAP-targeted radiopharmaceutical - an advanced therapy developed for precision oncology. This novel agent broadens Clarity’s clinical pipeline and provides a highly selective treatment option for cancers exhibiting elevated FAP expression, with the potential to enhance both diagnostic clarity and treatment efficacy. This milestone reflects Clarity’s ongoing commitment to developing radiopharmaceuticals that support personalized cancer care.

In March 2025, Telix Pharmaceuticals Ltd., an Australia-based radiopharmaceutical company, acquired a portfolio of fibroblast activation protein (FAP)-targeting theranostic radiopharmaceutical candidates developed by Professor Frank Rösch and his team at Johannes Gutenberg University Mainz. The financial terms of the deal were not disclosed. This acquisition is intended to leverage Telix’s global commercial capabilities and expertise in theranostics to accelerate the development of FAP-targeting agents. The acquired portfolio includes both preclinical and clinical-stage candidates designed for the imaging and treatment of various cancers. Johannes Gutenberg University Mainz, based in Germany, is recognized for its specialization in nuclear chemistry.

Major players in the fibroblast activation protein inhibitors market are Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals Inc., Prestige Consumer Healthcare Inc., SOFIE Biosciences Inc., Molecular Partners, FibroGen Inc., Elicio Therapeutics Inc., Huya Bioscience International, Agios Pharmaceuticals Inc., MedChemExpress, Boster Biological Technology, Nordic Nanovector, Ferronova, InvivoChem, PsiOxus Therapeutics, and Angion Biomedica Corp.

North America was the largest region in the fibroblast activation protein inhibitors market in 2024. The regions covered in fibroblast activation protein inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fibroblast activation protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Fibroblast activation protein (FAP) inhibitors are targeted therapies used to treat fibrosis-related conditions by blocking the activity of FAP, a protein involved in tissue scarring. As small-molecule inhibitors, they work by specifically inhibiting FAP to reduce the formation of excess fibrous tissue, thereby helping to preserve or improve organ function by slowing the progression of fibrosis.

The primary types of fibroblast activation protein inhibitors include small molecule inhibitors, monoclonal antibodies, and peptide inhibitors. Small molecule inhibitors are low molecular weight compounds that can effectively penetrate cells to inhibit FAP’s enzymatic activity. These inhibitors are being investigated for various conditions such as interstitial cystitis, Crohn’s disease, irritable bowel syndrome, chronic prostatitis, and others. They can be administered through different routes, including oral, intravenous, and subcutaneous methods. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, with use spanning multiple healthcare settings such as hospitals, homecare, specialty clinics, and more.

The fibroblast activation protein inhibitors market research report is one of a series of new reports that provides fibroblast activation protein inhibitors market statistics, including the fibroblast activation protein inhibitors industry global market size, regional shares, competitors with the fibroblast activation protein inhibitors market share, detailed fibroblast activation protein inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the fibroblast activation protein inhibitors industry. This fibroblast activation protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibroblast activation protein inhibitors market consists of sales of antibody-drug conjugates, radiolabeled inhibitors, and combination therapies targeting fibroblast activation protein. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.